Physician

Michael Riley Heaphy, M.D.

According to 2025 Medicare claims, Michael Heaphy, M.D. (NPI: 1821011057) practices dermatology in the Lima, OH market, with the plurality of this provider's patient population coming from Allen, OH. This provider's primary affiliated billing organization is WEST OHIO DERMATOLOGY, INC. (NPI: 1619070224; TIN: 341649211) and primary practice location at 45801-2967.

Heaphy's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 3,072 traditional Medicare patients, billed 20,216 HCPCS/CPT codes, and received $641,289 in Medicare payments. The top billing code was 11102 (Biopsy of related skin growth, first growth). Part D data shows 40 prescription claims across 18 beneficiaries totaling $50,970 in drug costs. Open Payments data shows 14 records totaling $319. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $1,028,174 to $641,289. Similarly, Part D prescription costs started with an early spike, then settled into a lower baseline, moving from $444,813 to $50,970. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$557K$1.1M2015 Medicare payment: $1,028,174 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $939,360 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $1,113,435 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $1,032,077 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $1,082,495 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $978,756 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $1,017,153 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $957,565 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $705,010 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $641,289 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20152,99321,530$1,028,174
20163,10421,852$939,360
20173,32024,115$1,113,435
20183,17421,919$1,032,077
20193,17523,246$1,082,495
20202,85221,013$978,756
20212,98022,699$1,017,153
20223,01621,741$957,565
20233,03320,348$705,010
20243,07220,216$641,289

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$258K$516K2015 Drug cost: $444,813 (USD; Tot_Drug_Cst)2016 Drug cost: $515,759 (USD; Tot_Drug_Cst)2017 Drug cost: $362,811 (USD; Tot_Drug_Cst)2018 Drug cost: $256,435 (USD; Tot_Drug_Cst)2019 Drug cost: $41,157 (USD; Tot_Drug_Cst)2020 Drug cost: $2,116 (USD; Tot_Drug_Cst)2021 Drug cost: $68,064 (USD; Tot_Drug_Cst)2022 Drug cost: $6,814 (USD; Tot_Drug_Cst)2023 Drug cost: $8,822 (USD; Tot_Drug_Cst)2024 Drug cost: $50,970 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015260780$444,813
2016226705$515,759
2017318776$362,811
2018242628$256,435
201958119$41,157
20202778$2,116
20212567$68,064
20223581$6,814
20231548$8,822
20241840$50,970

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
11102Biopsy of related skin growth, first growth9171,073$55
99212Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more1,1521,677$34
17000Destruction of precancer skin growth, 1 growth1,5192,231$33
88305Pathology examination of tissue using a microscope, intermediate complexity1,2642,498$21
17003Destruction of precancer skin growth, 2-14 growths1,2147,687$4

Top 5 Part D drugs in 2024

By total drug costs.

Part D summary data is connected for 2024, but public drug-level costs are not available, so a Top 5 by total drug costs cannot be shown.

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.14$319ABBVIE INC.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Michael Riley Heaphy, M.D.?

Tedicare shows public-source Medicare data for Michael Riley Heaphy, M.D. (NPI 1821011057), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michael Riley Heaphy, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Michael Riley Heaphy, M.D.?

Michael Riley Heaphy, M.D. is linked to WEST OHIO DERMATOLOGY, INC. (billing NPI 1619070224) in the available physician profile data.

Does Michael Riley Heaphy, M.D. have Open Payments data?

Michael Riley Heaphy, M.D. has 14 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.